UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

___________

FORM 8-K

___________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June~~December 309, ~~2020~~2021

Commission File Number: 000-26181

AngioGenex, Inc.

(Exact name of small business issuer as specified in its charter)


Nevada		86-0945116
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

425 Madison Ave., Suite 902, New York, New York 10017

(Address of principal executive offices)

(212) 644-2100

(Issuer's telephone number, including area code)

(Former name, former address and former fiscal year,

If changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Items to be Included in this Report

~~SECTION~~ITEM 51. ~~CORPORATE~~01 ~~GOVERNANCE~~Entry ~~AND~~into ~~MANAGEMENT~~a Material Definitive Agreement

~~ITEM~~Convertible ~~5.02~~Loans ~~Departure of Principal Officer; Appointment of Principal Officer~~Received

~~(d)~~On December 9, 2021, AngioGenex, Inc., entered into definitive agreements with two unaffiliated accredited investors and the CEO and Chairman of the Board Michael Aronstein, executing convertible promissory notes fully due and payable on October 31, 2023 in an amount of $260,000 at 7% interest per annum. ~~Appointment~~The Notes are convertible into unregistered securities, voluntarily by the Holders or automatically upon the completion of ~~Principal~~a ~~Officers~~financing of Fifteen Million Dollars or more.

OnThere ~~June~~were ~~30,~~no ~~2020~~fees, ~~Mr.~~commissions ~~Robert~~or ~~Dickey~~professional IVfees ~~was~~for ~~appointed~~services asrendered anin ~~Independent~~connection ~~Member~~with ofthe promissory note. The transaction was arranged and undertaken by the ~~Board~~officers of ~~Directors~~AngioGenex.

~~Mr.~~ITEM ~~Dickey is currently the Managing Director at Foresite Advisors, a financial advisory firm for life science companies that is based in Philadelphia~~3. ~~He is also on the Board and is Audit Committee Chair of Emmaus Life Sciences (EMMA) and is part of the Leadership Team at Cell One Partners Inc~~02. He ~~has~~Unregistered ~~more~~Sales ~~than 25 years~~ of ~~experience,~~Equity ~~primarily as a CFO or a Board member, leading life science and medical device companies, both private and public, ranging from early-stage development to commercial operations~~Securities. Advisory clients have included Aclipse, Panorama Medicine, Carisma, Vallon, NLS Pharmaceutics, Mercaptor, BeyondSpring and Sharp Edge Labs. Prior to becoming an advisor he served as full time CFO for multiple companies, including Caladrius Biosciences (CLBS), Tyme Technologies (TYME), StemCyte, Locus Pharmaceuticals and Protarga, Inc., among others. He also served on the Boards of Sanuthera and Protarga, which he sold to Daiichi Sankyo. Before that he spent 18 years in investment banking, mostly at Lehman Brothers, with a background split between M&A and capital markets transactions. Rob holds an AB from Princeton University and an MBA from The Wharton School, University of Pennsylvania.

~~Mr.~~The ~~Dickey~~information iscontained ~~experienced~~ in ~~all stages of the corporate lifecycle, including start-up operations, going public, high growth, turnarounds and exit strategies~~Item 1. ~~His~~01 ~~expertise~~above ~~includes~~is ~~public~~incorporated ~~and~~herein ~~private~~by financings, M&A, partnering/licensing transactions, project management, managing company’s finance and accounting functions, and Chapter 11 reorganizations, as well as interactions with Boards, venture capitalists, shareholders and Wall Streetreference.

~~SIGNATURES~~The securities underlying the Notes were sold pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D promulgated thereunder. Those securities have not been registered under the Securities Act

~~Pursuant~~ITEM to9.01 ~~the~~Financial ~~requirements~~Statements ofand ~~the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~Exhibits

~~AngioGenex, Inc.~~ (~~Registrant~~c) ~~Date~~Exhibits: ~~July 10, 2020 By: /s/ Michael Strage Michael Strage Chief Admin Officer~~


	10.1	Form of Convertible Promissory Note, entered into by the Company

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AngioGenex, Inc. (Registrant)

Date: December 15, 2021

By: /s/ Michael Strage

Michael Strage

Chief Admin Officer

Filing Compare · AngioGenex, Inc.